Marketing Group Presentation

1. Marketing Group Presentation • Cost Analysis by Anawat Pinisakul • Intellectual Property Laws in Thailand by Phanit Ratasuk • Health Insurance in Thailand by Chate Jaikunya • FDA Thai by Manaswee Arayasiri • Southeast Asia Market by Myat Htay Kyi • HIV in China by Wang Xiaofeng

2. Cost and Financing Aspects of Providing Anti-Retroviral Therapy Marketing Group of AIDS Drug By Mr. Anawat Pinisakul EVD998498 Advisor Dr. Maria Kartalou Dr. Suvit Loprasert

3. Today Presentation • Introduction • Background • Treatment of AIDS by drug • Contents • Cost and financing aspect • Cost-saving and cost-effectiveness • Conclusions

4. Introduction • The HIV/AIDS was first recognized in the early 1980s. • Treatment options were limited. • AZT drug (Zidovudine) was approved by USA’s FDA in 1987. • This drug is now widely used in North America, Europe and Australia • Other anti-retrovirals (ARVs)

5. Introduction • In contrast, ARVs are not yet widely available in developing countries. • Asia • Africa • Latin America • ARVs combination therapies • Prolong life • Prevent HIV-infected progression • Reduce transmission of HIV from mother to children

6. Contents • Cost of providing anti-retroviral therapy • Total cost implication of providing anti-retroviral therapy • Total cost implications of providing anti-retroviral therapy in comparison with available resources • Cost-saving potential and cost-effectiveness of anti-retroviral therapy • Financing anti-retroviral therapy

7. Cost of providing anti-retroviral therapy • Three types of drug • Nucleoside reverse transciptase inhibitors • Protease inhibitors • Non- Nucleoside reverse transciptase inhibitors

8. }

9. Cost of providing anti-retroviral therapy

10. Total cost implication of providing anti-retroviral therapy Estimated Number of People North America Oceania Sub-Saharan Africa Eastern Europe Northeast Asia Western Europe Latin America Caribbean SE Mediterranean Southeast Asia Geographic Region

11. Total cost implication of providing anti-retroviral therapy Estimated Cost ($billion) Northeast Asia Sub-Saharan Africa Eastern Europe North America Oceania Western Europe Latin America Caribbean SE Mediterranean Southeast Asia

12. Total cost implications of providing anti-retroviral therapy in comparison with available resources

13. Total cost implications of providing anti-retroviral therapy in comparison with available resources • Number of patients • Cost of treatment • GDP • Health expenditures

14. Cost-saving potential and cost-effectiveness of anti-retroviral therapy • Cost-saving potential • AZT therapy • Reduced health care costs in comparison with not receive drug • Triple-combination therapies • Cost save in 4.6 times per capita income • Cost-effectiveness • AZT therapy • Prolong life • Triple-combination therapies • Reduce medical costs

15. Financing anti-retroviral therapy • High cost with ARV therapy • Financing care may not be sufficient • Health care financing • Taxation • Social insurance system • Private insurance • User fees • Community financing schemes

16. Financing anti-retroviral therapy • Private insurance companies • Difficult for patient to receive helping • Employers in the USA try to exclude AIDS patients from group insurance polices • Public sector • In Maryland, Medicaid • 65% of AIDS patients

17. Conclusions • ARV therapy does appear affordable and cost-effective in high-income countries • Consideration • Number of HIV patients • Income of population • Type of drug • Government section

18. Thank You! • Dr. Maria Kartalou • Dr. Suvit Loprasert • MIT Staff • CRI Staff • Our Classes

19. THE END